Viking Therapeutics Q4 2025 Results: Pipeline Progress Takes Center Stage

Viking Therapeutics US92686J1060

Investor attention is fixed on Viking Therapeutics as the biopharmaceutical firm prepares to release its fourth-quarter and full-year 2025 financial results after the U.S. market closes today. The primary focus for shareholders will not be the anticipated quarterly loss, but rather management commentary on the company's clinical development pipeline. Specific updates regarding the promising candidate VK2735, which targets the competitive obesity therapeutics market, are highly sought after.

Trading activity has been volatile ahead of the announcement. The company's shares declined by approximately 2% on Tuesday, even as trading volume and discussions across financial platforms saw a noticeable increase. A conference call is scheduled for 10:30 PM Central European Time, during which the executive team is expected to provide insights into ongoing trial programs.

As a clinical-stage biotechnology company without significant product revenue, Viking Therapeutics is projected to report a quarterly loss per share in the range of $0.90 to $0.91. Consequently, the market is closely monitoring the company's cash position and, more critically, advancements in its key research initiatives.

The central item of interest is the Phase 3 VANQUISH trial investigating the subcutaneous formulation of VK2735, a dual GLP-1/GIP receptor agonist. Market participants are eager for any details on patient recruitment progress and potential timelines for data readouts. Attention also extends to the oral formulation of the drug; earlier in January, the company published detailed Phase 2 results from its VENTURE study in the medical journal Obesity.

Navigating a Competitive Landscape

Viking operates in a sector dominated by established players like Eli Lilly and Novo Nordisk. A core investment thesis for many holders revolves around the company's ability to successfully conclude late-stage trials and potentially secure a strategic partnership or acquisition.

Recent regulatory filings revealed that both the Chief Operating Officer and the Chief Financial Officer disposed of shares in January. While such transactions are commonplace in the biotech industry, investors scrutinize them carefully, especially preceding major clinical or financial catalysts.

The stock currently trades well below its peak levels from early 2024. The initial market euphoria surrounding GLP-1 class drugs has given way to a more measured assessment of execution and commercial risks.

Key Details for Investors

• Earnings Release: Wednesday, February 11, 2026 (after U.S. market close)
• Conference Call: 10:30 PM CET / 4:30 PM ET
• Estimated EPS Loss: Approximately -$0.90 to -$0.91
• Lead Drug Candidate: VK2735 (subcutaneous and oral formulations)
• Advanced Trial Phase: Phase 3 (VANQUISH program)

The market's reaction will likely hinge on management's statements concerning commercialization strategy and financial runway. Concrete updates on clinical trial progress, however, possess the greatest potential to move the share price.